Henlius and Amberstone Biosciences join forces on next-generation T-cell engagers for solid tumours

What's the deal? On 23 September 2026, Shanghai Henlius Biotech, a Hong Kong-listed Chinese biopharma, announced a global collaboration and licence agreement with Amberstone Biosciences, a US biotech, to develop next-generation T-cell engagers (TCEs) for solid tumours. TCEs are antibodies that bind both to cancer cells and to the body's own T cells, recruiting the immune system to kill tumours. The deal covers up to two tumour targets selected by Henlius. Amberstone's T-MATE platform will generate the preclinical candidates, and Henlius will lead later-stage research, development, manufacturing and global commercialisation. Amberstone receives an upfront payment, research fees, development, regulatory and sales milestones, plus single-digit royalties on sales. Reports put the deal's total potential value at up to $440 million.

Why it matters: T-cell engagers have transformed the treatment of blood cancers, but in solid tumours they have been held back because the proteins they target are also found on healthy tissue, causing severe side effects. Amberstone's T-MATE platform aims to solve this with a pH-sensitive switch: the molecule stays inert in normal, neutral tissue and only activates in the acidic environment that surrounds most solid tumours, widening the safety window. The deal gives Henlius — best known as a biosimilar maker — a route into a fast-moving immunotherapy class, while Amberstone gains a financially strong partner with manufacturing and global commercial reach.

Read more: Shanghai Henlius Biotech, 23 September 2026 · Fierce Biotech, 23 September 2026